Supernus Pharmaceuticals (SUPN) Scheduled to Post Quarterly Earnings on Monday

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of $0.26 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last released its earnings results on Wednesday, April 13th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.25). Supernus Pharmaceuticals had a return on equity of 6.75% and a net margin of 9.21%. On average, analysts expect Supernus Pharmaceuticals to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

SUPN traded up $0.24 during trading on Tuesday, reaching $29.12. 4,209 shares of the company’s stock were exchanged, compared to its average volume of 460,568. The company’s fifty day moving average price is $30.97 and its 200-day moving average price is $30.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.63 and a current ratio of 1.91. Supernus Pharmaceuticals has a fifty-two week low of $23.15 and a fifty-two week high of $34.50. The firm has a market capitalization of $1.55 billion, a PE ratio of 29.47 and a beta of 1.12.

A number of research firms have commented on SUPN. TheStreet lowered shares of Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, April 18th. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 4th. Finally, StockNews.com raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 18th.

Hedge funds have recently made changes to their positions in the company. Barclays PLC grew its holdings in shares of Supernus Pharmaceuticals by 24.2% in the 4th quarter. Barclays PLC now owns 77,598 shares of the specialty pharmaceutical company’s stock valued at $2,263,000 after buying an additional 15,098 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $2,196,000. California State Teachers Retirement System lifted its position in Supernus Pharmaceuticals by 2.9% in the 4th quarter. California State Teachers Retirement System now owns 71,871 shares of the specialty pharmaceutical company’s stock valued at $2,096,000 after acquiring an additional 2,034 shares in the last quarter. Marshall Wace LLP bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $1,695,000. Finally, Credit Suisse AG lifted its position in Supernus Pharmaceuticals by 1.2% in the 4th quarter. Credit Suisse AG now owns 52,584 shares of the specialty pharmaceutical company’s stock valued at $1,533,000 after acquiring an additional 644 shares in the last quarter.

Supernus Pharmaceuticals Company Profile (Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Stories

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.